NCT01332292 - Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Asthma

Interventions

DRUG

Fluticasone furoate

Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.

DRUG

Matching placebo

Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.

Trial Locations (5)

61761

GSK Investigational Site, Normal

80206

GSK Investigational Site, Denver

90630

GSK Investigational Site, Cypress

92647

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford